cell line
development

with leap-in transposase®

ATUM's Leap-In transposases and synthetic transposons enable a cost-effective, easily implemented cell line development workflow. The technology delivers high productivity pools and cell lines, resulting in consistent product quality. The Leap-In technology underpins ATUM's cell line development services and is also licensable for your in-house use.

Yield

With Leap-In technology generate highly productive stable pools. Pool titers are very predictive of the titers of final clonal lines.

Stability

Exceptional genetic stability leads to stable productivity of Leap-in-generated clonal cell lines. Derisk your downstream process development, scale-up and manufacturing.

Speed

Product quality and productivity are highly comparable between stable pools and derivative clones. Initiate analytical development, process development, and GLP toxicology studies early, shaving months off the CMC timeline.

Efficiency

Cell line development using Leap-In technology is less labor intensive and does not require automation. Many cell line development projects may be conducted simultaneously by a small team.

cldAsset 2

LEAP-IN TRANSPOSASE®

Leap-In Transposases Integrate Intact DNA Constructs into Active Chromatin

Leap-In transposases integrate single copies of the entire synthetic transposon into multiple transcriptionally active genomic loci. Expression constructs integrated by Leap-In transposases do not exhibit the rearrangements and concatemerization that are common, problematic hallmarks of random non-homologous recombination driven integrations. Maintaining structural integrity of the sequence integrated into the host genome ensures that regulatory elements remain associated with the appropriate open reading frames, and desired balances between multiple open reading frames are maintained.

How Leap-In Transposase Works

01

A synthetic transposon, comprising the expression construct and selection marker, flanked by inverted terminal repeats (ITRs).

02

Leap-In transposase recognizes its specific ITRs, binds and excises the transposon.

03

Leap-In transposase recognizes 4-base insertion sites across the host cell genone.

04

The intact transposon is inserted at up to 59 loci across the genome.

Expression Balancing and Optimization with VectorGPS®

The balance of expression for each subunit in a multi-subunit protein affects productivity and product quality. Compounding this complexity, there is often an incomplete correlation between the best ratios of transiently transfected genes, and the optimal stable expression of each subunit. Using our VectorGPS® design platform, we can design, synthesize and transfect several synthetic transposons in parallel, each harboring up to 4 independently-controlled, codon-optimized ORFs with altered expression ratios. Stable pool productivity and product quality analyses will reveal the optimal construct.

Leap-In Transposon
2 ORFs

Pools

Leap-In Transposon
3 ORFs

Pools

Leap-In Transposon
4 ORFs

Pool

Control of protein subunit expression ratios in 2-, 3- and 4-ORF Leap-In transposons.

CELL LINE DEVELOPMENT WORKFLOW

Our Hosts

ATUM currently uses two host cell lines with lineage traceability and documented provenance, are adapted to commercially-available chemically-defined serum-free formulations. No raw materials of animal origin are used during our CLD process.

- HD-BIOP3 GS null CHOK1 cell line from Horizon Discovery
- DG44 from the lab of Dr. Lawrence Chasin (Columbia University)



Stable Pool Selection

Leap-In transposase is very efficient. Most cells that are transfected with Leap-In transposons and transposase will integrate multiple copies of the transposon into their genomes. This results in rapid recovery of stable pools consisting of many very similar cells. This means that the productivity and product quality of clones derived from these pools are similar to the pools themselves. Process and analytical development can therefore start as early as a few weeks post-transfection. Material for toxicology studies can be prepared from stable pools to further shorten overall CMC timelines.

Productivity

Product Quality

Product quality (glycan relative abundance %, charge %) and productivity is comparable between stable pool and derivative clones.

Clone Isolation

In stable pools generated by Leap-In technology, the clonal distributions within the pools are strongly biased towards high productivity. This reduces the number of clones that need to be tested to at most a few hundred.

166 clones

Static 96 well plate

Clones

22 clones

24 deep-well scale, 7 day fed batch clone ranking

Clones

8 clones

Highest ranked clones, 125 ml shake, 14 day fed batch

Clones

Screening, characterizing and ranking fewer clones eliminates the need to invest in expensive, high-throughput instrumentation and allows more cell line development projects to be managed simultaneously.

Stability Testing

Leap-In transposase mRNA is co-transfected with the synthetic transposon into the cell. The mRNA is translated and the Leap-In transposase protein acts to integrate the transposon into the host genome. Once the transposase mRNA has been degraded through the normal cellular RNA turnover pathways, there is no way for the cell to generate transposase to mobilize the transposon, so the integration structures are stably maintained. Because each integration contains a single copy of the transposon, there is no instability resulting from concatemer recombination or repeat-induced silencing.

Clonal cell lines are grown for 60 populations doublings then assayed for genetic stability by ddPCR, and productivity stability. The majority of clones created using Leap-In technologies exhibit no significant decreases in their volumetric productivity and integrated transposon copy number.

Productivity maintained

Copy number maintained

Pie charts show the maintenance of productivity and transposon copy number in clonal cell lines after 60 population doublings. Data is taken from 47 clones created using Leap-In technologies. All clones retained at least 70% of their initial productivity and transposon copy number.

CELL LINE DEVELOPMENT
TIMELINE

1 - 3 weeksDESIGN & SYNTHESIS OFOPTIMIZED SYNTHETICTRANSPOSONGene synthesis & vector constructionPool generation & characterizationProtein (mg)6 - 9 weeksISOLATE, CHARACTERIZEAND RANKSTABLE CLONESCell line generation4 - 5 weeksRCB MANUFACTURING& RELEASEStable poolClonal cell lineRCBBEGIN PROCESS DEVELOPMENT & ANALYTICAL DEVELOPMENT Protein (g)~9- 10 weeksGENETIC STABILITY STUDIES60 PDProtein (g)(Clone derived)Monoclonality established (VIPS, Solentim)RCB & Stability studies4 - 6 weeksESTABLISHMENT & CHARACTERIZATION OF HIGHLY PRODUCTIVEREPRESENTATIVE STABLE POOLS

Licensing leap-in
transposase®

Bring the advantages of Leap-In technology to your in-house cell line development. The unique Leap-In transposase technology is covered by many issued and pending US patents, ensuring a broad integrated portfolio of related tools to maximize your cell line development success. The portfolio includes not only the Leap-In transposon/transposase itself but also complementing tools such as vector optimization, unique vector elements, codon optimization and more to provide you with our state-of-the-art bioengineering expertise. For the currently issued patents and related claims, please see our patents list.

We offer three convenient tiers of licensing to meet your research and commercialization needs. Under all licenses, Leap-In transposase mRNA and synthetic transposon DNA are purchased from ATUM. Your gene and vector designs are supported by our experienced Leap-In team and synthesized by ATUM to maximize your chance for success.

Evaluation

Test and optimize the Leap-In technology in your labs. Convert to a full research license after 6 months or terminate if the Leap-In technology is not for you. Quick low-cost opportunity to take Leap-In system out for a spin.

Research

Simple annual license fee. Access to existing and new transposon and transposase technology as it is continuously developed at ATUM. This licensing tier is great for all your research use only (RUO) applications.

Commercialization

Licensing tier for commercial production of your protein pharmaceutical or similar. Payable on cell lines that enable commercialization of your therapeutic, diagnostic or product. Pay annually, as a single lump sum, or attached to clinical milestones.

Contact us for quotes or to answer any questions you may have.

Have a question?
Let's talk.

ATUM customer support scientists are available to discuss cloning strategies, gene design constraints, bioinformatics analyses, and other molecular biology/biotechnology concerns.

Call

Corporate Headquarters
(Newark, California)
+1 650 853 8347

Email

We generally reply within a few hours.

info@atum.bio

Chat with us